Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2019 Jul 25

PMID 31336846

Citations 23

Authors

Solene Fernandez

Vanessa Desplat

Arnaud Villacreces

Amelie V Guitart

Noel Milpied

Arnaud Pigneux

Isabelle Vigon

Jean-Max Pasquet

Pierre-Yves Dumas

Affiliations

Soon will be listed here.

Abstract

Acute myeloid leukemia (AML) is a myeloid malignancy carrying a heterogeneous molecular panel of mutations participating in the blockade of differentiation and the increased proliferation of myeloid hematopoietic stem and progenitor cells. The historical "3 + 7" treatment (cytarabine and daunorubicin) is currently challenged by new therapeutic strategies, including drugs depending on the molecular landscape of AML. This panel of mutations makes it possible to combine some of these new treatments with conventional chemotherapy. For example, the FLT3 receptor is overexpressed or mutated in 80% or 30% of AML, respectively. Such anomalies have led to the development of targeted therapies using tyrosine kinase inhibitors (TKIs). In this review, we document the history of TKI targeting, FLT3 and several other tyrosine kinases involved in dysregulated signaling pathways.

Citing Articles

Narrative review of targetable features of pediatric acute myeloid leukemia from molecular and metabolic perspectives.

Trabal A, Chandra J Pediatr Med. 2025; 4.

PMID: 39877586 PMC: 11774499. DOI: 10.21037/pm-20-98.

and study of FLT3 inhibitors and their application in acute myeloid leukemia.

Carranza-Aranda A, Jave-Suarez L, Flores-Hernandez F, Huizar-Lopez M, Herrera-Rodriguez S, Santerre A Mol Med Rep. 2024; 30(6).

PMID: 39392050 PMC: 11475230. DOI: 10.3892/mmr.2024.13353.

Nucleic acid therapeutics as differentiation agents for myeloid leukemias.

Kovecses O, Mercier F, McKeague M Leukemia. 2024; 38(7):1441-1454.

PMID: 38424137 PMC: 11216999. DOI: 10.1038/s41375-024-02191-0.

Transient TKI-resistant CD44+pBAD+ blasts undergo intrinsic homeostatic adaptation to promote the survival of acute myeloid leukemia .

Xu Y, Baylink D, Chen C, Tan L, Xiao J, Park B Front Oncol. 2023; 13:1286863.

PMID: 38023123 PMC: 10664142. DOI: 10.3389/fonc.2023.1286863.

Optimization of Tyrosine Kinase Inhibitor-Loaded Gold Nanoparticles for Stimuli-Triggered Antileukemic Drug Release.

Tatar A, Nagy-Simon T, Tigu A, Tomuleasa C, Boca S J Funct Biomater. 2023; 14(8).

PMID: 37623644 PMC: 10455807. DOI: 10.3390/jfb14080399.

References

Roginskaya V, Zuo S, Caudell E, Nambudiri G, Kraker A, Corey S . Therapeutic targeting of Src-kinase Lyn in myeloid leukemic cell growth. Leukemia. 1999; 13(6):855-61. DOI: 10.1038/sj.leu.2401429. View

Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M . Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia. 1999; 13(9):1352-8. DOI: 10.1038/sj.leu.2401484. View

Yang W, Collette Y, Nunes J, Olive D . Tec kinases: a family with multiple roles in immunity. Immunity. 2000; 12(4):373-82. DOI: 10.1016/s1074-7613(00)80189-2. View

van Dijk T, van den Akker E, Amelsvoort M, Mano H, Lowenberg B, von Lindern M . Stem cell factor induces phosphatidylinositol 3'-kinase-dependent Lyn/Tec/Dok-1 complex formation in hematopoietic cells. Blood. 2000; 96(10):3406-13. View

Robinson D, Wu Y, Lin S . The protein tyrosine kinase family of the human genome. Oncogene. 2000; 19(49):5548-57. DOI: 10.1038/sj.onc.1203957. View

Smolich B, Yuen H, West K, Giles F, Albitar M, Cherrington J . The antiangiogenic protein kinase inhibitors SU5416 and SU6668 inhibit the SCF receptor (c-kit) in a human myeloid leukemia cell line and in acute myeloid leukemia blasts. Blood. 2001; 97(5):1413-21. DOI: 10.1182/blood.v97.5.1413. View

Smith C, Islam T, Mattsson P, Mohamed A, Nore B, Vihinen M . The Tec family of cytoplasmic tyrosine kinases: mammalian Btk, Bmx, Itk, Tec, Txk and homologs in other species. Bioessays. 2001; 23(5):436-46. DOI: 10.1002/bies.1062. View

Blume-Jensen P, Hunter T . Oncogenic kinase signalling. Nature. 2001; 411(6835):355-65. DOI: 10.1038/35077225. View

Levis M, Allebach J, Tse K, Zheng R, Baldwin B, Smith B . A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood. 2002; 99(11):3885-91. DOI: 10.1182/blood.v99.11.3885. View

10.

Scheijen B, Griffin J . Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease. Oncogene. 2002; 21(21):3314-33. DOI: 10.1038/sj.onc.1205317. View

11.

Gilliland D, Griffin J . Role of FLT3 in leukemia. Curr Opin Hematol. 2002; 9(4):274-81. DOI: 10.1097/00062752-200207000-00003. View

12.

Weisberg E, Boulton C, Kelly L, Manley P, Fabbro D, Meyer T . Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412. Cancer Cell. 2002; 1(5):433-43. DOI: 10.1016/s1535-6108(02)00069-7. View

13.

Manning G, Whyte D, Martinez R, Hunter T, Sudarsanam S . The protein kinase complement of the human genome. Science. 2002; 298(5600):1912-34. DOI: 10.1126/science.1075762. View

14.

Kainz B, Heintel D, Marculescu R, Schwarzinger I, Sperr W, Le T . Variable prognostic value of FLT3 internal tandem duplications in patients with de novo AML and a normal karyotype, t(15;17), t(8;21) or inv(16). Hematol J. 2003; 3(6):283-9. DOI: 10.1038/sj.thj.6200196. View

15.

Ofarrell A, Abrams T, Yuen H, Ngai T, Louie S, Yee K . SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood. 2003; 101(9):3597-605. DOI: 10.1182/blood-2002-07-2307. View

16.

Fiedler W, Mesters R, Tinnefeld H, Loges S, Staib P, Duhrsen U . A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia. Blood. 2003; 102(8):2763-7. DOI: 10.1182/blood-2002-10-2998. View

17.

Stirewalt D, Radich J . The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer. 2003; 3(9):650-65. DOI: 10.1038/nrc1169. View

18.

Lannutti B, Shim M, Blake N, Reems J, Drachman J . Identification and activation of Src family kinases in primary megakaryocytes. Exp Hematol. 2003; 31(12):1268-74. DOI: 10.1016/j.exphem.2003.09.009. View

19.

Fiedler W, Serve H, Dohner H, Schwittay M, Ottmann O, Ofarrell A . A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood. 2004; 105(3):986-93. DOI: 10.1182/blood-2004-05-1846. View

20.

Lennartsson J, Jelacic T, Linnekin D, Shivakrupa R . Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells. 2004; 23(1):16-43. DOI: 10.1634/stemcells.2004-0117. View